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ABSTRACT The NF-κB family of transcription factors is a well-established regulator of the 
immune and inflammatory responses and also plays a key role in other cellular processes, in-
cluding cell death, proliferation, and migration. Conserved residues in the trans-activation 
domain of RelA, which can be posttranslationally modified, regulate divergent NF-κB func-
tions in response to different cellular stimuli. Using rela−/− mouse embryonic fibroblasts re-
constituted with RelA, we find that mutation of the threonine 505 (T505) phospho site to ala-
nine has wide-ranging effects on NF-κB function. These include previously described effects 
on chemotherapeutic drug-induced apoptosis, as well as new roles for this modification in 
autophagy, cell proliferation, and migration. This last effect was associated with alterations in 
the actin cytoskeleton and expression of cellular migration–associated genes such as WAVE3 
and α-actinin 4. We also define a new component of cisplatin-induced, RelA T505–dependent 
apoptosis, involving induction of NOXA gene expression, an effect explained at least in part 
through induction of the p53 homologue, p73. Therefore, in contrast to other RelA phospho-
rylation events, which positively regulate NF-κB function, we identified RelA T505 phospho-
rylation as a negative regulator of its ability to induce diverse cellular processes such as 
apoptosis, autophagy, proliferation, and migration.
INTRODUCTION
The NF-κB family of transcription factors is an important regulator of 
the cellular response to stress and infection, functioning as control-
lers of the immune and inflammatory responses, as well as key cel-
lular processes such as apoptosis, proliferation, and adhesion 
(Hayden and Ghosh, 2008). Aberrantly active NF-κB subunits are 
associated with a wide range of inflammatory diseases (Kumar et al., 
2004). Moreover, NF-κB can contribute to the growth, survival, and 
malignancy of numerous cancer cell types while also significantly 
affecting the response of tumors to many types of chemotherapy 
and ionizing radiation (Kim et al., 2006).
NF-κB complexes in mammalian cells consist of homodimers 
and heterodimers formed from five subunits: RelA (p65), RelB, c-Rel, 
p50/p105 (NF-κB1), and p52/p100 (NF-κB2) (Hayden and Ghosh, 
2004). In the absence of an inducing stimulus, NF-κB complexes are 
typically held in an inactive form, bound to one of a family of IκB 
inhibitory proteins (Hayden and Ghosh, 2004). A number of path-
ways can lead to activation of NF-κB, and, of these, the classical (or 
canonical) pathway, which induces expression of RelA-containing 
complexes, is the best defined (Hayden and Ghosh, 2004; Perkins, 
2007). The classic pathway is typically activated by inflammatory cy-
tokines such as tumor necrosis factor α (TNFα) and interleukin β, as 
well as bacterial products such as bacterial lipopolysaccharide 
(Hayden and Ghosh, 2004). However, in response to other stimuli, 
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RelA-containing complexes can become activated through different 
routes. For example, under many circumstances, DNA damage re-
sults in nuclear localization of NF-κB essential modulator (NEMO) 
and phosphorylation by ataxia telangiectasia mutated (ATM), with 
subsequent relocation back to the cytoplasm, where it activates the 
IκB kinase (IKK) complex (Wu and Miyamoto, 2007). IKK-indepen-
dent, atypical pathways of activation have also been described, 
such as the p38 mitogen-activated protein kinase/CK2–mediated 
induction of NF-κB in response to UV light (Kato et al., 2003).
Posttranslational modifications can have a major effect on the 
function of NF-κB subunits (Perkins, 2006). The IKK subunits them-
selves can phosphorylate NF-κB proteins and modulate their tran-
scriptional activity (Perkins, 2006, 2007). However, parallel signaling 
pathways can also modify NF-κB subunits, thus providing a mecha-
nism to integrate NF-κB/IKK activity with other cellular processes 
(Perkins, 2006, 2007). Modification of NF-κB subunits can have di-
verse effects, including induction of protein degradation, release 
from IκB, and enhancement of DNA binding, as well as transcrip-
tional effects, such as stimulating or inhibiting coactivator/corepres-
sor binding (Perkins, 2006; O’Shea and Perkins, 2008). This can have 
dramatic effects on the consequences of NF-κB induction. For ex-
ample, RelA has a strong antiapoptotic effect following TNFα stimu-
lation but can stimulate cell death following treatment with some 
inducers of DNA damage (Campbell et al., 2004, 2006; Perkins and 
Gilmore, 2006; Strozyk et al., 2006; Wu and Miyamoto, 2008; Thay-
aparasingham et al., 2009). We and others have demonstrated that 
NF-κB subunits can both induce and repress the expression of the 
same gene targets, depending on the context of their activation 
(Campbell et al., 2004, 2006; Thayaparasingham et al., 2009) or cell 
cycle stage (Barre and Perkins, 2007), and the gene induction or re-
pression correlates with changes in RelA phosphorylation.
The C-terminal RelA transactivation domain (TAD) is responsible 
for mediating most of its transcriptional effects in cells. Within this 
domain are a number of highly conserved known and putative phos-
phorylation sites (Campbell and Perkins, 2004; O’Shea and Perkins, 
2008). It was suggested that different patterns of phosphorylation 
within the RelA TAD provide an explanation for the altered functions 
of RelA (Perkins, 2006, 2007; Moreno et al., 2010; O’Shea and 
Perkins, 2010). In particular, we previously defined the threonine 
505 (T505) residue as having an important regulatory role under 
some conditions: T505 can become inducibly phosphorylated by 
the checkpoint kinase Chk1 in response to cisplatin and induction of 
the tumor suppressor p14ARF (Rocha et al., 2003, 2005; Campbell 
et al., 2006). Moreover, T505 is phosphorylated by Chk1 in S phase 
as a consequence of activation of the DNA-replication checkpoint 
(Barre and Perkins, 2007). T505 phosphorylation is stimulus specific 
and is not seen after TNFα treatment or with other inducers of DNA 
damage such as UV or daunorubicin. Our previous data suggested 
that T505 phosphorylation induced a proapoptotic form of RelA 
that could facilitate cell death through transcriptional repression of 
antiapoptotic target genes such as Bcl-xL. Here we reconstituted 
rela−/− mouse fibroblasts with wild-type and T505 mutant forms of 
RelA. We confirm the important role that T505 plays in mediating a 
proapoptotic effect of RelA in response to cisplatin and extend this 
analysis to reveal roles in the regulation of autophagy, cellular prolif-
eration, and migration.
RESULTS
Reconstitution of rela−/− mouse fibroblasts
Previously we observed inducible phosphorylation of RelA at T505 
following cisplatin treatment of U-2 OS human osteosarcoma cells 
(Campbell et al., 2006). Concurrently, we observed repression of the 
NF-κB target gene Bcl-xL, consistent with a proapoptotic role for 
RelA under these conditions. Moreover, mutation of RelA at T505 
abolished cisplatin-mediated repression of the RelA TAD in lu-
ciferase reporter assays. Together, these results suggested that 
phosphorylation of RelA at T505 following cisplatin treatment medi-
ates a proapoptotic effect and contributes to cisplatin-induced cyto-
toxicity. To obtain more definitive data concerning the role of T505 
phosphorylation after cisplatin treatment, we reconstituted immor-
talized rela−/− mouse fibroblasts by retroviral transduction with wild-
type and T505 mutated forms of human RelA (Figure 1A and Sup-
plemental Figure S1A).
Consistent with our previous results, where we showed T505 phos-
phorylation during S phase of the cell cycle (Barre and Perkins, 2007), 
in the untreated asynchronous reconstituted rela−/− cells, RelA dis-
played a basal level of T505 phosphorylation. This was enhanced al-
most twofold following 12 h of cisplatin treatment (Figure 1A). Muta-
tion of the threonine 505 residue to either alanine (T505A) or aspartic 
acid (T505D) reduced the phospho-antibody signal, although some 
background binding to RelA was still detectable. We also confirmed 
phosphorylation of endogenous RelA at T505 in untreated asynchro-
nous wild-type Rela MEF cells that was further increased following 
cisplatin treatment (Supplemental Figure S1B). To demonstrate that 
the RelA was functional in the reconstituted rela−/− cells, we examined 
the response of RelA to TNFα. We observed reconstitution of the 
NF-κB complex by electrophoretic mobility shift assay (EMSA) follow-
ing TNFα treatment (Supplemental Figure S1C) and resistance to 
TNFα-induced apoptosis (Figure 1B). Mutation of T505 had no effect 
on the antiapoptotic NF-κB response to TNF in these cells.
A feature of some isolates of immortalized rela−/− mouse fibro-
blasts is that they display a mild transformed phenotype and can 
form colonies in soft agar (Gapuzan et al., 2005). This is also a fea-
ture of the isolate of rela−/− cells used here (Figure 1C), which also 
contain mutant p53, as judged by the high levels of p53 protein 
seen by Western blot. Consistent with previous data from the 
Gilmore laboratory (Gapuzan et al., 2005), reconstitution of these 
cells with RelA suppressed soft agar colony formation, and this pro-
cess was also not affected by mutation of T505 (Figure 1C).
We next investigated the response to cisplatin treatment. As 
predicted by our previous observations, we found that reintroduc-
tion of RelA enhanced cisplatin-induced cell death (Campbell 
et al., 2006). Of importance, the T505A mutation abolished the 
RelA-dependent enhancement of death, whereas the T505D mu-
tation did not (Figure 1D and Supplemental Figure S2A). There 
was no difference in viability in the untreated control cells between 
the groups (Figure 1D). Similarly, T505A mutation was also protec-
tive against cell death caused by camptothecin and rimcazole but 
did not protect as well against cell death following treatment with 
methylmethanesulfonate (MMS; Supplemental Figure S2B). To 
confirm that these results did not occur due to variability in the 
individual clones, we examined the effect of cisplatin treatment on 
cell survival in wild-type Rela MEF cells transiently transfected with 
an empty RSV vector or with RSV containing human RelA, T505A, 
or T505D. To reduce background from endogenous Rela, these 
cells were treated with an small interfering RNA (siRNA) targeting 
mouse Rela 48 h prior to transient transfection (Supplemental 
Figure S2C). As in the reconstituted rela−/− cells, transient transfec-
tion with RelA enhanced cisplatin-mediated cell death, whereas 
transfection with a T505A-containing plasmid abolished the RelA-
dependent enhancement of cell death (Supplemental Figure S2D). 
These data confirm the importance of T505 phosphorylation in 
mediating the response of RelA to specific DNA-damaging agents 
and, in particular, cisplatin.
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Mutation of T505 abolishes RelA-dependent induction  
of apoptosis
Our previous data suggested that T505 phosphorylation regulates 
the apoptotic response (Campbell et al., 2006). Confirming a 
proapoptotic effect of RelA in the reconstituted rela−/− cells following 
cisplatin treatment, we observed enhanced caspase 3 activation in 
the presence of wild-type RelA (Figure 2, A and B). The T505A muta-
tion abolished this RelA-dependent induction of caspase 3. Similar 
data were seen with wild-type Rela MEFs transfected with RelA, 
T505A, or T505D (Supplemental Figure S2E). As seen in the rela−/− 
MEF cells, annexin staining was also reduced in the T505A MEF cells 
following cisplatin treatment when compared with wild-type RelA 
cells (Supplemental Figure S2F). In the reconstituted rela−/− MEFs, 
caspase 3 activation in response to cisplatin treatment in the T505D 
cells was reduced in comparison to the wild-type RelA cells but 
showed similar annexin staining (Figure 2B and Supplemental Figure 
S2F). Annexin staining detects phosphatidylserine exposure in both 
caspase-dependent and caspase-independent apoptosis (Ferraro-
Peyret et al., 2002). Given that these cells displayed the same level of 
enhanced cell death as seen with wild-type RelA (Figure 1D and 
Supplemental Figure S2A), the T505D cells may be dying through a 
caspase-independent pathway. We therefore investigated potential 
alternative mechanisms through which these cells might be dying.
Recently it has become apparent that autophagy, which can 
have both prosurvival and prodeath effects, depending on the cel-
lular context, can contribute to cell killing (Mathew et al., 2007; 
Levine and Kroemer, 2008). We therefore investigated whether au-
tophagy might be involved in cisplatin-induced cell death in RelA 
reconstituted rela−/− cells. Yeast Atg8 and its mammalian homo-
logue LC3 are ubiquitin-like modifiers that are localized on isolated 
membranes and play crucial roles in the formation of autophago-
somes. Conversion of soluble LC3-I to lipid-bound LC3-II is associ-
ated with the formation of autophagosomes. We therefore analyzed 
the effects of RelA and cisplatin treatment on LC3 conversion in 
these cells. By Western blot, we observed, in both wild-type RelA 
and T505D reconstituted cells, an enhanced basal level of the LC3-II 
form that was further increased following cisplatin treatment (Figure 
2A). By contrast, the control rela−/− cells and T505A reconstituted 
cells displayed a lower level of the LC3-II form, which, although still 
inducible by cisplatin treatment, never reached the levels seen in 
the wild-type RelA or T505D cells. This effect was analyzed more 
quantitatively by acridine orange staining, which undergoes a color 
conversion in autophagic vesicles that can be detected by fluores-
cence-activated cell sorting (FACS; Paglin et al., 2001; Kanzawa 
et al., 2003). In agreement with the Western blot data, both higher 
basal level and cisplatin-induced levels of autophagy were observed 
FigURE 1: Reconstitution of rela−/− mouse fibroblast cells with RelA restores responsiveness to TNFα treatment. 
(A) Cisplatin stimulates RelA T505 phosphorylation in RelA reconstituted rela−/− MEF cells. Cells from individual MEF 
clones were treated with cisplatin (4 μg/ml) for 4, 8, or 12 h, and phosphorylation of RelA T505 was determined in 
whole-cell extracts (20 μg) by Western blotting. (B) Mutation of RelA at T505 protects rela−/− MEFs from TNFα-induced 
apoptosis. Cells were treated for 6 h with 50 ng/ml TNFα, and caspase 3 activity was detected in 25 μg of cell lysates 
using the Promega CaspasACE Kit. Data are shown as mean ± SD and expressed as caspase activity relative to the 
untreated control sample. (C) RelA T505 mutations still reverse the neoplastic phenotype of rela−/− MEFS. A total of 
1 × 105 cells were plated in 0.3% agar and incubated for 21 d. Colonies in the agar were counted at 2.5× magnification 
using a Leica microscope. Data are expressed as colonies formed relative to the rela−/− MEF cells. (D) T505A mutation 
protects cells from cisplatin-induced cell death. Cells were treated with 4 μg/ml cisplatin for 48 h, and the percentage of 
living cells was determined by trypan blue exclusion assay. Data are presented as mean ± SD and expressed as 
percentage survival. All data are representative of a minimum of three independent experiments.
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in the wild-type RelA and T505D reconstituted cells (Figure 2C). 
Confirming that the signal generated by acridine orange staining 
resulted from autophagy, this was inhibited by treatment with the 
autophagy inhibitor 3-methyladenine (3-MA) but not by the caspase 
inhibitor Z-VAD. However, 3-MA treatment did not totally protect 
against cell death in these cells, indicating that this is not an expla-
nation for the enhanced level of cell death seen in wild-type RelA 
and RelA T505D reconstituted cells (Supplemental Figure S2A). This 
is consistent with our previous observation on the role of autophagy 
in response to cisplatin treatment (Barre and Perkins, 2010). A 
preapoptotic, protective lag phase in response to cisplatin treat-
ment of renal cells has been shown to result from autophagy 
(Kaushal et al., 2008; Periyasamy-Thandavan et al., 2008). Moreover, 
autophagy has also been shown to have a protective effect against 
apoptosis induced in tumor cell lines (Harhaji-Trajkovic et al., 2009; 
Barre and Perkins, 2010).
Regulation of NOXA gene expression by RelA  
and T505 dependence
Previously we observed that RelA can repress the expression of the 
antiapoptotic gene Bcl-xL in response to cytotoxic drugs, including 
cisplatin (Campbell et al., 2004, 2006). In agreement with our previ-
ous data, in the reconstituted rela−/− MEFs we also observed sig-
nificant RelA-dependent repression of Bcl-xL mRNA and protein 
levels, which was impaired in the T505A cells following cisplatin 
treatment (Figure 3A and Supplemental Figure S3A). Analysis of the 
expression of other genes with a role in 
apoptosis indicated that NOXA (also known 
as PMA-induced protein 1, PMAIP1) was in-
duced in these cells in a RelA-dependent 
manner upon cisplatin treatment (Figure 3B 
and Supplemental Figure S3B). Moreover, 
consistent with the effects on caspase 3 ac-
tivation, T505A mutation inhibited RelA-de-
pendent induction of this gene in both re-
constituted rela−/− and wild-type MEF cells 
(Figure 3B and Supplemental Figure S3B). 
We previously showed that the RelA-depen-
dent repression of the Bcl-xL gene results 
from RelA binding and recruitment of his-
tone deacetylase (HDAC) to the Bcl-xL pro-
moter (Campbell et al., 2006). The NOXA 
promoter region contains a number of puta-
tive NF-κB–binding sites (Supplemental Fig-
ure S3C), and to determine whether RelA 
directly regulates NOXA gene expression 
we examined RelA binding to the NOXA 
promoter using chromatin immunoprecipi-
tation. After 16 h of cisplatin treatment there 
was a moderate increase in RelA binding to 
the NOXA promoter in the wild-type RelA 
and T505A reconstituted rela−/− cells (Sup-
plemental Figure S3D). We did not see any 
changes in HDAC1 binding at this time; 
however, this does not exclude the possibil-
ity that other classes of deacetylases are in-
volved in this response. Recently it was 
shown that NOXA expression is regulated 
by p73 and that NF-κB is required for this 
induction (Martin et al., 2009; O’Prey et al., 
2010). p73 is a member of the p53 tumor 
suppressor family and shares considerable 
homology and overlapping functions with p53. It is believed to act 
as a tumor suppressor and can bind to p53 gene targets and regu-
late apoptosis, although it has also been implicated in development 
and immunity (Davis and Dowdy, 2001). Of interest, NF-κB has also 
been implicated in regulation of p73 stability in response to TNFα 
treatment (Kikuchi et al., 2006) and may represent another way in 
which NF-κB can mediate both antiapoptotic and proapoptotic ac-
tions. To determine whether mutation of RelA can alter p73 levels 
and thus also influence NOXA levels, we examined the level of p73 
mRNA in the reconstituted rela−/− and wild-type MEF cells. As with 
NOXA, there was a significant increase in p73 mRNA levels in both 
the RelA and T505D MEF cells that was impaired in the T505A and 
rela−/− cells (Figure 3C and Supplemental Figure S3E), which sug-
gests that RelA may regulate NOXA expression primarily through 
regulation of p73 levels.
To test this hypothesis, we examined the effect of p73 knock-
down on cisplatin-induced NOXA mRNA levels in wild-type Rela 
MEF cells and rela−/− MEF cells reconstituted with human RelA. We 
observed a basal induction of NOXA following cisplatin treatment 
that was RelA independent, as seen in the rela−/− cells, that was fur-
ther induced in the presence of RelA (Figure 3B and Supplemental 
Figure S3B). Of importance, knockdown of p73 in both the reconsti-
tuted rela−/− and wild-type MEF cells (Supplemental Figure S3, F 
and H) significantly inhibited the RelA-dependent, cisplatin-induced 
increase in NOXA levels, reducing them to levels similar to that seen 
in the rela−/− or T505A cells, but did not effect the RelA-independent 
FigURE 2: Mutation of T505 abolishes RelA-dependent induction of apoptosis. 
(A) Reconstituted rela−/− MEF cells were treated with 4 μg/ml cisplatin for 16, 24, or 48 h,  
and 20 μg of a whole-cell extract was analyzed by Western blot for levels of total and cleaved 
caspase 3, LC3-I and LC3-II isoforms, RelA. and β-actin. (B) RelA T505A mutation protects 
against cisplatin-induced apoptosis. Cells were treated for 24 h with 4 μg/ml cisplatin, and 
caspase 3 activity was detected in 25 μg of cell lysates using the Promega CaspasACE kit. Data 
are presented as mean ± SD and expressed as caspase activity relative to the dimethyl sulfoxide 
(DMSO) control sample. (C) The development of acidic vesicular organelles, indicative of 
autophagy, was examined following treatment with 4 μg/ml cisplatin, with or without 1-h 
pretreatment with the inhibitor 3-MA (1 mM) or Z-VAD (20 μM) for 24 h. Cells were stained with 
acridine orange, and the intensity of the red fluorescence was measured using FACS. Data are 
expressed as mean ± SD. All data represent a minimum of three individual experiments.
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induction of NOXA (Figure 3D and Supplemental Figure S3G). Our 
data suggest two mechanisms for the induction of NOXA following 
cisplatin treatment: a basal induction that is both RelA and p73 inde-
pendent and a RelA/p73 dependent effect that can further enhance 
NOXA induction. We propose that the RelA/p73-dependent in-
crease in NOXA expression seen will, together with repression of 
Bcl-xL, contribute to cisplatin-induced cell death.
Mutation of T505 alters cellular proliferation and migration
Our data demonstrated a role for RelA T505 phosphorylation in reg-
ulation of cell death following treatment with DNA-damaging agents. 
To determine whether this residue may contribute to other processes 
associated with tumorigenesis, we also examined the effect of muta-
tion of T505 on cell proliferation and migration. The ability of cancer 
cells to evade proliferative blocks and to invade and migrate into 
surrounding tissues is recognized as a key hallmark of tumorigenesis 
and is a crucial step in the formation of cancer metastases (Hanahan 
and Weinberg, 2000). Cellular migration involves reorganization 
of the actin cytoskeleton, which provides the force for cell mobility 
and is initialized by the specialized structures of the lamellipodia 
and filopodia (reviewed in Vignjevic and 
Montagnac, 2008). Analysis of cell prolifera-
tion by FACS showed that RelA T505A muta-
tion decreased the proportion of G1-phase 
cells and increased G2/M-phase cells when 
compared with the wild-type RelA reconsti-
tuted rela−/− MEF cells (Figure 4A). Similarly, 
use of an MTS assay showed a significant in-
crease in proliferation in the T505A cells 
when compared with the wild-type RelA and 
T505D cells (Figure 4B). Furthermore, analy-
sis of cell migration in a wound-healing assay 
showed that migration is increased in the 
T505A MEF cells (Figure 4, C and D). This 
was independent of cell proliferation, as in-
hibition of proliferation with mitomycin C did 
not effect the rate of migration when com-
pared with untreated cells (Figure 4, C and 
D). This effect could also be seen when plas-
mids containing wild-type or RelA T505 mu-
tations were transfected into both wild-type 
Rela MEF and human U-2 OS osteosarcoma 
cells, where the inhibition of migration seen 
upon RelA expression was lost with the 
T505A mutation (Supplemental Figure S4, A 
and B). The increase in migration in T505A 
cells was also accompanied by an increase in 
the presence of filamentous actin fibers in 
these cells (Figure 5).
To determine how this effect of T505A 
mutation on cell migration is regulated, we 
examined the expression of a number of 
genes required for cellular migration. There 
was a significant increase in the mRNA lev-
els of WAVE3, α-actinin 4, cortactin, N-
Wasp, and integrin-α5 in the T505A cells 
compared with wild-type RelA cells (Figure 
6A and Supplemental Figure S5A). How-
ever, there was no effect on other migration-
associated genes, such as ARP2 (Supple-
mental Figure S5A). Similar data were 
observed in wild-type Rela MEFs transfected 
with RelA, T505A, or T505D plasmids (Figure 6B and Supplemental 
Figure S5B). To determine whether these gene changes were due 
directly to RelA, we examined binding of RelA to NF-κB sites in the 
promoters of WAVE3, α-actinin 4, N-Wasp, and integrin-α5, using 
chromatin immunoprecipitation (Supplemental Figure S6A). There 
was significantly increased binding of RelA to all of the promoters in 
RelA reconstituted rela−/− MEFs when compared with the T505A 
mutant cells (Figure 6C and Supplemental Figure S6B). This sug-
gests that these genes are RelA targets and that binding of RelA 
may be involved in the repression of these genes. Overall our data 
indicate that RelA can alter cellular migration through regulation of 
specific migration genes and that phosphorylation of Thr505 is im-
portant in this regulation.
DISCUSSION
It is now understood that the role of NF-κB in regulation of cell 
survival and death is more complex than originally thought, with 
NF-κB capable of acting to both promote and inhibit apoptosis, 
depending on the stimulus and cell type (Perkins and Gilmore, 
2006). Our data are consistent with previous reports of NF-κB and 
FigURE 3: RelA regulation of NOXA gene expression. (A, B) RelA T505A mutation induces 
antiapoptotic and reduces proapoptotic gene expression following cisplatin treatment. 
Reconstituted rela−/− MEF cells were treated with cisplatin (4 μg/ml) or DMSO as a control for 
4 h (Bcl-xL) or 16 h (NOXA). Following cisplatin treatment, RelA T505A induced, whereas RelA 
and T505D repressed, expression of the antiapoptotic gene Bcl-xL (A; p < 0.05, n = 5/group). 
Conversely, RelA T505A repressed, whereas RelA and T505D induced, expression of the 
proapoptotic gene NOXA (B; p < 0.01, n = 4/group). RNA was extracted from individual clones 
(A) and from pooled MEF cells (B). mRNA data are normalized relative to 18S mRNA and 
expressed as fold induction compared with the DMSO control. (C) mRNA was prepared from 
individual MEF clones following treatment with 4 μg/ml cisplatin for 16 h. The induction in 
p73 mRNA levels in the cisplatin-treated samples relative to the untreated controls was 
determined by real-time PCR. (D) Knockdown of p73 mRNA impairs the induction of NOXA 
following cisplatin treatment. In rela−/− MEF cells reconstituted with wild-type RelA, p73 was 
knocked down by siRNA, and NOXA mRNA levels were examined by real-time PCR following 
16 h of cisplatin treatment. All PCR data are normalized relative to 18S mRNA and expressed 
relative to the DMSO control sample. Data are presented as mean ± SD and represent a 
minimum of three individual experiments. *p < 0.05, **p < 0.01, ***p < 0.001.
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RelA stimulating apoptosis following specific forms of genotoxic 
stress (Campbell et al., 2004; Wu and Miyamoto, 2008; Martin 
et al., 2009; O’Prey et al., 2010). Although we previously identified 
Bcl-xL repression as a component of this process, here we also 
demonstrate RelA-dependent induction of the proapoptotic gene 
NOXA. Of importance, T505A mutation reduced the level of 
NOXA mRNA following cisplatin treatment (Figure 3B and Supple-
mental Figure S3B). Although NOXA was previously shown to be a 
RelA target gene in cortical neurons, with RelA regulating NOXA 
promoter activity and NOXA mRNA levels in response to cerebral 
ischemia (Inta et al., 2006), in this study we reported only moder-
ate RelA binding to the NOXA promoter in wild type RelA and 
FigURE 4: RelA T505 mutation affects cell proliferation and migration in MEF cells. (A, B) T505A mutation of RelA 
restores proliferation to levels matching the rela−/− MEF cells. Cells were seeded into six-well (FACS) or 96-well (MTS) 
plates, and growing MEF cells were analyzed for cell cycle stage using propidium iodide FACS (A) and for proliferation 
after 4 d by MTS assay (B). Data are presented as mean ± SD relative to the day-zero control. (C, D) Migration is 
increased in RelA T505A MEFs. Individual clones of the reconstituted rela−/− MEF cells were seeded in each side of an 
Ibidi culture insert and incubated for 24 h. Cells were pretreated with mitomycin C (C; 30 μM) or with culture media 
alone (D) for 30 min before removal of the insert. Cells were photographed at the time of insert removal and 6 h after 
insert removal and examined for cell migration. Scale bar, 500 μm. All experiments are representative of a minimum of 
three independent experiments. *p < 0.05, **p < 0.01.
3038 | A. Msaki et al. Molecular Biology of the Cell
can determine specific cell death decisions in response to differ-
ent stimuli.
We also observed RelA T505–dependent regulation of cellular 
proliferation and migration. Previous data from our group showed 
that multiple NF-κB subunits with differential posttranslational modifi-
cations can control cell cycle progression through regulation of pro-
teins such as cyclin D1, c-Myc, and p21WAF1 (Schumm et al., 2006; 
Barre and Perkins, 2007). Phosphorylation of RelA at T505 occurred 
primarily during S phase and was associated with decreased cyclin 
D1, c-myc, and skp2 expression (Barre and Perkins, 2007). In this study 
we showed that the RelA T505A mutation increased cell proliferation 
compared with wild-type RelA and T505D mutant cells (Figure 4, A 
and B). Furthermore, we also demonstrated RelA T505–dependent 
regulation of cell migration in both reconstituted rela−/− and wild-type 
Rela MEFs, as well as in U-2 OS cells. Here wild-type RelA suppressed 
cell migration, whereas mutation of T505 to alanine abolished this 
effect, with enhanced levels of migration being seen (Figure 4, C and 
D, and Supplemental Figure S4, A and B). This is not the first report to 
implicate NF-κB in cell migration. However, it is the first study to dem-
onstrate the direct role of an individual NF-κB subunit, RelA, and the 
role of a specific phosphorylatable residue. Previously, loss of IKKβ 
was shown to increase invasion and migration (Chen et al., 2006). 
Conversely, loss of IKKα reduced cell migration, adhesion, and inva-
siveness, possibly through an NF-κB–independent direct effect of 
IKKα on target genes such as maspin (Merkhofer et al., 2010; Mahato 
et al., 2011). We also found RelA T505–dependent regulation of the 
mRNA expression of a number of migration-associated genes (Figure 
6, A and B, and Supplemental Figure S5, A and B). Using chromatin 
immunoprecipitation (ChIP) analysis, we observed RelA binding to 
NF-κB elements in the promoters of these genes (Figure 6C and Sup-
plemental Figure S6B), implying that the mRNA changes result at 
least in part through a direct effect of RelA on these genes.
This study demonstrated the importance of T505 phosphoryla-
tion as a negative regulator of RelA-dependent cellular processes. 
Overall, the effect of the T505A mutation is to create a form of RelA 
exhibiting enhanced oncogenic characteristics, leading to enhanced 
cellular proliferation and migration, together with enhanced resis-
tance to chemotherapeutic treatments. We propose that pathways 
such as RelA T505 phosphorylation normally act to suppress NF-κB 
activity and oncogenicity. However, loss of these pathways during 
tumorigenesis will lead to forms of NF-κB with enhanced oncogenic 
abilities capable of promoting the development of malignant, meta-
static cancer cells.
MATERIALS AND METHODS
Cells and DNA/siRNA transfection
Cell lines were grown in 10% fetal calf serum (Life Technologies, 
Carlsbad, CA)/DMEM (Lonza, Basel, Switzerland) for no more than 
30 passages. DNA transfections were performed using polyethylen-
imine (Polysciences, Warrington, PA), and siRNA duplex oligonucle-
otides were synthesized by Eurofins MWG Operon (Ebersberg, 
Germany) and transfected using Interferin (Polyplus-transfection, 
Illkirch, France) as per manufacturer’s instructions.
Reconstitution of rela−/− cells
Immortalized rela−/− MEFs were obtained from Ron Hay (University 
of Dundee, Dundee, United Kingdom). RelA cDNAs were inserted 
into the PIRESpuro-deNotI, viral vector plasmid, which, together 
with the VSV-G, viral envelope protein expressing plasmid, and 
CMVR8.91, the viral packaging plasmid, were transfected into HEK 
293 cells to generate lentiviral particles essentially as described 
(Zufferey et al., 1998).
T505A reconstituted rela−/− cells (Supplemental Figure S3D), 
suggesting additional mechanisms. Indeed, consistent with a 
previous report of RelA-dependent NOXA expression by p73 
(O’Prey et al., 2010), we found a significant RelA T505–depen-
dent increase in p73 mRNA. Furthermore, knockdown of p73 
could significantly inhibit only the cisplatin-induced, RelA-depen-
dent and not the basal RelA-independent induction of NOXA 
(Figure 3D and Supplemental Figure S3G). Our data suggest that 
in response to cisplatin treatment, NOXA mRNA levels are in-
duced by two mechanisms: a basal induction that is independent 
of RelA and a RelA/p73 mechanism that further enhances NOXA 
induction. Overall our data suggest that by coordinating patterns 
of gene induction and repression, RelA phosphorylation at Thr505 
FigURE 5: RelA T505 mutation alters the actin cytoskeleton. RelA 
mutation increases filamentous actin fibers in the reconstituted 
rela−/− MEF cells. Cells were stained with Alexa Flour 488 phalloidin 
and DAPI, and F-actin was examined using microscopy. The intensity 
of phalloidin staining was quantified by densitometry using ImageJ. 
All experiments are representative of a minimum of three 
independent experiments. **p < 0.01.
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(PBS). Caspase activity was analyzed with 
the CaspasACE Kit (Promega, Madison, WI), 
following the manufacturer’s instructions, 
using 25 μg of protein extract. Annexin V 
staining was analyzed with the Annexin V 
FITC Apoptosis Detection Kit (Calbiochem, 
La Jolla, CA) using 0.5 × 106 cells, following 
the manufacturer’s instructions.
Crystal violet stain
Cells were counted, and equal numbers of 
cells were grown in six-well plates for 48 h 
before treatment with chemotherapeutic 
drugs for 48 h. Surviving cells were washed 
once with PBS and fixed with 100% metha-
nol for 10 min at room temperature before 
staining with 0.05% (wt/vol) crystal violet in 
25% methanol for 5 min. Plates were repeat-
edly washed with distilled water, allowed to 
air dry, and scanned for analysis.
Acridine orange assay for autophagy
To quantify the development of acidic ve-
sicular organelles in cells following DNA 
damage, cells were stained with acridine or-
ange and the intensity of the red fluores-
cence measured as described previously 
(Paglin et al., 2001; Kanzawa et al., 2003). 
Green (510–530 nm) and red (>650 nm) flu-
orescence emission from cells illuminated 
with blue (488 nm) excitation light was mea-
sured with a FACSCalibur (BD Biosciences, 
San Diego, CA), using CellQuest software.
Soft agar assays to assess colony 
formation
Cells were counted, and 1 × 105 cells were 
mixed with molten agar (0.3% wt/vol final 
concentration) in DMEM medium and 
poured onto a layer of 0.3% (wt/vol) set agar 
in a six-well dish. The agar was allowed to 
set at room temperature before incubation 
at 37°C for 21 d. Colonies were photo-
graphed, stained with neutral red (Sigma-
Aldrich) for 1 h at 37°C, and counted.
Migration/wound-healing assays
Cells were seeded at a density of 3 × 104 cells 
on each side of an Ibidi culture insert for live 
cell analysis (Ibidi, Munich, Germany), with a 
500 μM separation between each side of the well, and allowed to 
grow for 24 h. Cells were pretreated with or without 30 μM mitomycin 
C for 30 min before removal of the insert, and following removal of 
the insert cells were incubated in DMEM also containing media alone 
or media with 30 μM mitomycin C. Cells were photographed using a 
Powershot A640 camera (Canon, Lake Success, NY) connected to an 
Axiovert 40C microscope using the 10× objective (Zeiss, Thornwood, 
NY) at insert removal (0 h) and following 6 and 24 h of incubation.
Phalloidin staining and fluorescence microscopy for F-actin
Cells were seeded on coverslips for 48 h, washed with PBS, and 
fixed with 3.7% formaldehyde. After a further wash with PBS the 
HEK 293 cell–generated viral supernatant was mixed with 
4 μg/ml polybrene (Sigma-Aldrich, St. Louis, MO) and was used to 
infect 5 × 105 rela−/− MEFs in a 10-cm dish containing 5 ml of me-
dia. Selection for reconstituted rela−/− MEFs was performed with 
4 μg/ml puromycin (Sigma-Aldrich). Experiments were performed 
as indicated on pooled populations of stably transduced cells or on 
isolated clones.
Caspase and annexin V assays
To determine whether the cells were dying by apoptosis, both ad-
herent and floating cells were harvested by centrifugation, and cell 
pellets were washed once in ice-cold phosphate-buffered saline 
FigURE 6: RelA T505 mutation alters migration-associated genes in MEF cells. (A, B) RelA 
T505A mutation alters expression of migration-associated genes. mRNA was extracted from 
individual reconstituted rela−/− MEF clones (A) and wild-type Rela MEFs transfected with a RelA, 
T505A, or T505D plasmid (B), and mRNA levels of WAVE3 and α-actinin 4 were examined by 
quantitative PCR. PCR data are normalized relative to 18S mRNA and expressed relative to the 
rela−/− (A) or RSV (B) control samples. (C) RelA binds to the promoter of WAVE3 and α-actinin 4. 
RelA binding to the promoters of WAVE3 and α-actinin 4 was examined in reconstituted 
rela−/− MEF cells, using chromatin immunoprecipitation. ChIP data were normalized to the 
individual input samples and are expressed relative to a Gal4 control. Data are presented as 
mean ± SD. All experiments are representative of a minimum of three independent experiments. 
*p < 0.05, **p < 0.01, ***p < 0.001.
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cells were permeabilized with 0.1% Triton X-100, washed twice with 
PBS, and stained with Alexa Fluor 488 phalloidin (1:200; Invitrogen, 
Carlsbad, CA) for 20 min at room temperature. Coverslips were 
washed twice with PBS and mounted with 4′,6-diamidino-2-
phenylindole mounting media (Vectashield, Vector Laboratories, 
Burlingame, CA). Images were taken on a DeltaVision Spectris wide-
field deconvolution microscope, using softWoRx software (Applied 
Precision, Seattle, WA).
Other assays
Transient transfections, siRNA knockdown, EMSAs, trypan blue, and 
MTS assays of cell viability, RNA extraction, real-time quantitative 
reverse transcription–PCR, protein extracts, Western blots, FACS, 
and ChIP were all performed as described previously (Rocha et al., 
2003; Rocha et al., 2005; Campbell et al., 2006; Schumm et al., 
2006; Barre and Perkins, 2007). Information on oligonucleotides 
used is shown in Supplementary Methods.
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